Core Viewpoint - The company has entered into a licensing and collaboration agreement with Windward Bio's subsidiary, granting exclusive rights for the development and commercialization of QX027N outside of specific regions in China, with potential payments totaling up to $700 million [1] Group 1 - The agreement allows LE2025 Therapeutics AG to develop and commercialize QX027N globally, excluding mainland China, Taiwan, Hong Kong, and Macau [1] - The total potential payments include an upfront payment, equity in Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in the licensed regions, amounting to up to $700 million [1] - QX027N is a long-acting dual-specific antibody targeting TSLP and IL-13, developed independently by the company [1] Group 2 - The company successfully initiated Phase I clinical trials for QX027N on December 12, 2025, with the first subject enrolled in China [1]
荃信生物-B(02509.HK)就QX027N的开发及商业化签订协议 有权获高达7亿美元付款